| Deal value | $7M |
|---|---|
| Share of market cap | 2.2% |
| Share of annual revenue | 160.9% |
Key highlights
- Total potential payments reach $7.1 million, including an upfront fee and a $1.0 million milestone for Australian approval
- Celairis gains exclusive rights across territories with an estimated population of 725 million people
- Ocugen receives high single-digit royalties and a 50% share of gross profits from net sales in the region
- Ocugen retains sole manufacturing rights and expects to finalize a formal supply agreement within 90 days
- Topline data from the Phase 3 LiMeliGht clinical trial is currently anticipated in the first quarter of 2027
What Is the Licensing Deal?
Ocugen has granted Sydney-based Celairis Therapeutics an exclusive, non-sublicensable license to commercialize OCU400 in several key Pacific and Southeast Asian markets. The agreement covers Australia, New Zealand, and member states of the Association of Southeast Asian Nations, including Singapore, Malaysia, Thailand, the Philippines, Vietnam, and Indonesia. This partnership focuses on the use of the modifier gene therapy for the treatment of retinitis pigmentosa in humans. Under the terms, Celairis assumes responsibility for all regional regulatory submissions, market access initiatives, and commercial activities within these jurisdictions, expanding the global reach of Ocugen's flagship ophthalmic candidate.
Licensing Terms
The financial structure consists of an upfront license fee and milestone payments totaling $7.1 million. Specifically, $6.1 million is tied to the upfront fee and the delivery of positive topline results from the Phase 3 LiMeliGht trial. An additional $1.0 million is contingent upon product approval by the Therapeutic Goods Administration in Australia. Beyond these payments, Ocugen is entitled to high single-digit royalties on net sales and a 50% share of gross profits. The agreement remains in effect for 20 years following the first commercial sale or until the expiration of relevant patent rights and regulatory exclusivities.
Strategic Fit
This collaboration represents Ocugen's third strategic regional partnership for OCU400, aimed at establishing a global commercial footprint ahead of potential regulatory approvals. By leveraging local expertise in Australia and ASEAN markets, Ocugen reduces its direct operational burden in complex regulatory environments. The company remains focused on its primary clinical milestones, specifically the ongoing Phase 3 trial. Ocugen maintains control over the global safety database and the manufacturing process, ensuring quality consistency across all territories while benefiting from the established infrastructure of regional distributors like Celairis to maximize patient access following any future approval.
Financial Context
Ocugen operates within the biotechnology sector with a current market capitalization of approximately $329.8 million. The company reported annual revenue of $4.413 million and recently saw its stock price climb 34.07% over a one-week period. Trading at $0.9721, the stock's Relative Strength Index of 59.2 suggests it is currently in a neutral momentum zone. This licensing revenue provides additional capital as the company prepares its Biologics License Application in the U.S. and Marketing Authorization Application in Europe. The upcoming data readout in early 2027 remains the critical catalyst for unlocking the milestone payments associated with this deal.
Down 20.5% since our story on 10 Nov: $0.97 when we broke it → $0.77 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.79 |
|---|---|
| 20 Oct | $0.81 |
| 21 Oct | $0.81 |
| 22 Oct | $0.79 |
| 23 Oct | $0.74 |
| 26 Oct | $0.71 |
| 27 Oct | $0.76 |
| 28 Oct | $0.78 |
| 29 Oct | $0.74 |
| 30 Oct | $0.70 |
| 2 Nov | $0.72 |
| 3 Nov | $0.74 |
| 4 Nov | $0.88 |
| 5 Nov | $0.82 |
| 6 Nov | $0.93 |
| 9 Nov | $0.97 |
| 10 Nov | $0.95 |
| 11 Nov | $0.96 |
| 12 Nov | $0.87 |
| 13 Nov | $0.83 |
| 16 Nov | $0.77 |
Management commentary
“This agreement marks our third strategic regional partnership for OCU400, underscoring the growing momentum behind our global access strategy and bringing our potential one-time treatment gene therapy closer to patients around the world.”
“Ocugen is the kind of partner Celairis was built for: a late-stage program, a clear strategy for reaching patients globally, and a conviction we share that geography should not decide access to new medicines.”
| Share price | $0.97 |
|---|---|
| Market cap | $330M |
| Revenue (annual) | $4M |
| 1-month price change | -0.51% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Ocugen, Inc. announcing an exclusive license agreement with Celairis Therapeutics.
Track Ocugen, Inc. live
Get the next Ocugen, Inc. SEC filing seconds after it lands.




